Citation

Kubilius RA, Kaplick PM, Wotjak CT. Learn. Mem. 2018; 25(9): 446-454.

Affiliation

Neuronal Plasticity Research Group, Department of Stress Neurobiology and Neurogenetics, Max Planck Institute of Psychiatry, 80804 Munich, Germany.

Copyright

(Copyright © 2018, Cold Spring Harbor Laboratory Press)

DOI

10.1101/lm.046870.117

PMID

30115766

Abstract

The prerequisites for responsible cannabis use are at the heart of current inquiries into cannabis decriminalization by policy makers as well as academic and nonacademic stakeholders at a global scale. Δ⁹-tetrahydrocannabinol (Δ⁹-THC), the prime psychoactive compound of the cannabis sativa, as well as cannabimimetics that resemble the pharmacological properties and psychological effects of Δ⁹-THC, lend themselves handsomely to the preclinical scrutiny of reward-related behavior because they carry marked translational value. Although a functional dichotomy of the psychological effects of Δ⁹-THC (rewarding versus aversive) has been abundantly reported in place conditioning (PC) paradigms, and might be best attributed to a dose-dependence of Δ⁹-THC, most PC studies with Δ⁹-THC feature no significant effects at all. Therefore, after decades of rigorous research, it still remains undetermined whether Δ⁹-THC generally exerts rewarding or aversive effects in rodents. Here, we set out to extrapolate the commonly alleged dose-dependence of the rewarding and aversive effects of Δ⁹-THC from the existing literature, at the behavioral pharmacological level of analysis. Specifically, our meta-analysis investigated: (i) the alleged bidirectional effects and dose-dependence of Δ⁹-THC in the PC test; (ii) methodological inconsistencies between PC studies; and (iii) other pharmacological studies on cannabinoids (i.e., dopamine release, anxiety, stress, conditioned taste aversion, catalepsy) to substantiate the validity of PC findings. Our findings suggest that: (i) Δ⁹-THC dose-dependently generates rewarding (1 mg/kg) and aversive (5 mg/kg) effects in PC; (ii) an inconsistent use of priming injections hampers a clear establishment of the rewarding effects of Δ⁹-THC in PC tests and might explain the seemingly contradictory plethora of nonsignificant THC studies in the PC test; and (iii) other pharmacological studies on Δ⁹-THC substantiate the dose-dependent biphasic effects of Δ⁹-THC in PC. A standardized experimental design would advance evidence-based practice in future PC studies with Δ⁹-THC and facilitate the pointed establishment of rewarding and aversive effects of the substance.

© 2018 Kubilius et al.; Published by Cold Spring Harbor Laboratory Press.

Language: en